

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



REDESIGNATION OF DIRECTOR AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

REDESIGNATION OF DIRECTOR

IVD Medical Holding Limited (the “**Company**” together with its subsidiaries, the “**Group**”) hereby announces that Ms. Tai Yang has been redesignated from the position of independent non-executive director of the Company (a “**Director**”) to executive Director with effect from 20 October 2025 (the “**Redesignation**”).

Biography of Ms. Tai is set out below:

Ms. TAI Yang (郟洋), aged 31, has been an independent non-executive Director since 1 July 2025. Ms. Tai graduated from Beijing Foreign Studies University with a bachelor’s degree in management in July 2016. She was conferred a master’s degree in engineering management by the Peking University in July 2024. She was designated a Certified Management Accountant by the Institute of Certified Management of the Institute of Management Accountants of the United States of America in March 2022. She was previously a non-practising member of The Chinese Institute of Certified Public Accountants, which was conferred to her in January 2023.

Ms. Tai has been a director of Zdeer Health Pte. Ltd. since August 2024. She is a partner of Wuhan Zdeer Xincheng Technology Partnership (Limited Partnership) and an executive director of Zdeer Health Technology (Henan) Co., Ltd.. Her other working experiences in the past include: the secretary to the board of directors and a finance responsible person of Zdeer Health Industry (Shenzhen) Co., Ltd., the secretary to the board of directors of Zdeer Industry (Hubei) Co., Ltd., a senior consultant of the advisory department of Ernst & Young (China) Advisory Limited Beijing Branch from March 2018 to October 2019, and worked in PWC International Assignment Services (Shanghai) Ltd. from November 2016 to February 2018.

In respect of the Redesignation, Ms. Tai will enter into a service agreement with the Company for a term of three years commencing from 20 October 2025 (to replace the existing letter of appointment dated 30 June 2025) until terminated by not less than three months' notice in writing served by either party on the other. She is also subject to retirement by rotation and re-election at the annual general meeting in accordance with the Company's articles of association. Pursuant to the service agreement, Ms. Tai is entitled to receive remuneration of HK\$30,000 per month and is eligible to receive discretionary bonuses and is entitled to other benefits in kind, allowances and to participate in provident funds (if applicable). Ms. Tai's remuneration was recommended by the remuneration committee of the Company (the "**Remuneration Committee**") and approved by the board of Directors (the "**Board**") in accordance with the Company's remuneration policy for Directors, with reference to her roles, duties and responsibilities, her performance and background, as well as the comparable market practices with reference to the Group's emolument policy for the Directors, and are subject to revision in future by the decision of the Board based on the recommendation of the Remuneration Committee.

Ms. Tai has also confirmed that, save as disclosed in this announcement, as of the date of this announcement, (i) she does not have any relationship with any of the Company's Directors, senior management, or substantial or controlling shareholders (as defined under the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange (the "**Listing Rules**")); (ii) she has not held any directorships in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the preceding three years; (iii) she does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iv) there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Listing Rules. The Company is not aware of any other matters relation to the Redesignation that need to be brought to the attention of the shareholders of the Company.

CHANGE IN COMPOSITION OF THE BOARD COMMITTEES

In light of the Redesignation, the following changes to the Board committees have taken effect on 20 October 2025:

1. Ms. Tai Yang ceased to be a member of the Remuneration Committee, and Mr. Zhang Jianlei has been appointed as a member of the Remuneration Committee; and

2. Ms. Tai Yang has resigned as chairman of the nomination committee of the Company (the “**Nomination Committee**”) but will continue to be a member of the Nomination Committee, and Mr. Zhang Jianlei has been appointed as the chairman of the Nomination Committee.

Biography of Mr. Zhang is available in the announcement of the Company dated 30 June 2025.

By order of the Board
IVD Medical Holding Limited
Lin Xianya
Executive Director

Hong Kong, 20 October 2025

As at the date of this announcement (and following the Redesignation mentioned in this announcement becoming effective), the Board comprises four executive directors, namely, Mr. Lin Xianya, Mr. Chan Siu Kei Ken, Mr. Law Kim Fai and Ms. Tai Yang, two non-executive directors, namely, Ms. Yao Haiyun and Mr. Liu Fei and four independent non-executive directors, namely, Dr. Zhong Renqian, Dr. Wong Sze Lok, Mr. Xu Da and Mr. Zhang Jianlei.

In this announcement, certain Chinese names of institutions, natural persons or other entities have been translated into English and included as unofficial translations for identification purposes only. In the event of any inconsistency, the Chinese names shall prevail.